Sign in
Taking peopleNo phase

AI-powered ECG Analysis Using Willem™ Software in High-risk Cardiac Patients (WILLEM)

Key facts

Who runs it
Idoven 1903 S.L.
Where
Netherlands and Spain13 sites in 2 countriesChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
5,342 people, planned
Started
4 Apr 2023
Expected to end
Dec 2026
Type of study
Observational, 2 groups
Treatments tested
  • AI-powered ECG analysis to detect cardiac arrhythmic episodes
Record updated
6 November 2026

Who can take part

Age
4 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Patient presenting relevant cardiac arrhythmias and cardiac patterns (including supraventricular tachycardias, abnormal ECG patterns, ventricular tachycardias, ventricular fibrillation, pulseless electrical activity or asystole among others) that have been recorded with at least one short-term ECG medical device according to guidelines with ≥1 signal-channel
  • Patient with suspected or diagnosed acute/chronic cardiac diseases (including patients with heart failure, patients with history of cardiac arrhythmias, patients with probable coronary artery diseases, patients with cardiomyopathies, patients with pacemakers or implantable cardioverter-defibrillators (ICD), patients with indication of pacemaker or ICD in current or short-term phase, patients participating in other interventional clinical investigation, patients with hemodynamic instability or acute coronary syndromes, pregnant patients, patients with cancer and chemotherapy, patients with life-expectancy lower than 24 months, patients with in or out-of-hospital cardiac arrest with ventricular fibrillation as first documented rhythm)
  • At least one ECG tracing that can be exported in raw data
  • Signed informed consent. Patients unable to consent, it will be requested to an authorized relative

Who cannot take part

  • Unwillingness or inability to sign study written informed consent
  • Unavailable or suboptimal quality of the electrocardiographic signal in raw data

This trial has no sites in United States.

It has sites in 2 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

WILLEM is a multi-center, prospective and retrospective cohort study.

Read full original descriptionShow less

The study will assess the performance of a cloud-based and AI-powered ECG analysis platform, named Willem™, developed to detect arrhythmias and other abnormal cardiac patterns. The main questions it aims to answer are:

1. A new AI-powered ECG analysis platform can automatice the classification and prediction of cardiac arrhythmic episodes at a cardiologist level. 2. This AI-powered ECG analysis can delay or even avoid harmful therapies and severe cardiac adverse events such as sudden death.

The prerequisites for inclusion of patients will be the availability of at least one ECG record in raw data, along with patient clinical data and evolution data after more than 1-year follow-up.

Cardiac electrical signals from multiple medical devices will be collected by cardiology experts after obtaining the informed consent. Every cardiac electrical signal from every subject will be reviewed by a board-certified cardiologist to label the arrhythmias and patterns recorded in those tracings. In order to obtain tracings of relevant information, >95% of the subjects enrolled will have rhythm disorders or abnormal ECG's patterns at the time of enrollment.

The 2 groups in the trial

  • Train group

    Consecutive patients admitted to the hospital due to cardiac disorders (retrospective and prospective) with at least one relevant ECG record \>10 sec in raw data will be used to design new methodologies and algorithms for cardiac patterns recognition.

    Treatment: AI-powered ECG analysis to detect cardiac arrhythmic episodes

  • Test group

    Consecutive patients admitted to the hospital due to cardiac disorders (retrospective and prospective) with at least one relevant ECG record \>10 sec in raw data will be used to evaluate performance of methodologies aiming to avoid overfitting. Every 10 patients included in Train group; a new patient is included in the test group.

    Treatment: AI-powered ECG analysis to detect cardiac arrhythmic episodes

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Evaluation of Electrocardiographic Data From High-risk Cardiac Patients Using Willem™ Cardiologist-level Artificial Intelligence Software. WILLEM Trial.
Record updated
6 November 2026